Major depression is accompanied by cognitive changes as well as alterations in multiple physical functions. The inflammatory system is altered generally toward a pro-inflammatory state. Antidepressants are associated with a decrease in this proinflammatory state. This study aims to generate pilot data concerning a possible link between cognition, inflammation and response to treatment. The cognitive function of subjects with major depression will be tested before and after treatment with duloxetine. Inflammatory markers will be measured at both time points.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
20
Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
Centre de Recherche Fernand Seguin
Montreal, Quebec, Canada
RECRUITINGHôpital Maisonneuve Rosemont
Montreal, Quebec, Canada
NOT_YET_RECRUITINGCognitive function measured by CANTAB
Correlation between cytokines and cognitive function
Time frame: 12 weeks
pain inhibition
Correlation between depression, antidepressant treatment status, inflammation and inhibition of perception of pain stimulus
Time frame: 12 weeks
Allostatic load
Correlation between depressive symptoms, antidepressant treatment status and allostatic load
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.